Naito K, Kobayashi M, Okumura M, Ikeda Y, Mitomo Y, Oguri T, Tanaka M, Ohara K, Kodera Y, Ohno R
2nd Department of Internal Medicine, Meitetsu Hospital.
Jpn J Antibiot. 1990 Aug;43(8):1371-80.
Imipenem/cilastatin sodium (IPM/CS), a newly developed carbapenem antibiotic, was administered to a total of 152 patients with severe infections complicating hematological disorders, of whom 138 patients are included in the present analysis of efficacy and 152 in that of safety. Most of the underlying diseases were acute leukemia (76/138), and most patients suffered from sepsis or suspicion of sepsis (84/138). Out of 138 patients in whom efficacy was evaluable, responses were excellent in 41 patients, good in 55, fair in 19, and poor in 23. The overall clinical efficacy rate was 69.6% (96/138). Prior antibiotic treatment and peripheral neutrophil count had significant effects on the clinical response. The overall eradication rate of bacteria was 76.2%. Adverse reactions were observed in 15 patients (9.9%) and abnormal laboratory test results in 19 patients (12.5%). From the above findings, IPM/CS is considered to be a useful antibiotic for the treatment of severe infections accompanying hematopoietic disorders.
亚胺培南/西司他丁钠（IPM/CS）是一种新开发的碳青霉烯类抗生素，共应用于152例伴有血液系统疾病的严重感染患者，其中138例纳入本疗效分析，152例纳入安全性分析。大多数基础疾病为急性白血病（76/138），大多数患者患有败血症或疑似败血症（84/138）。在138例可评估疗效的患者中，41例疗效极佳，55例良好，19例一般，23例较差。总体临床有效率为69.6%（96/138）。既往抗生素治疗和外周血中性粒细胞计数对临床反应有显著影响。细菌总体清除率为76.2%。15例患者（9.9%）出现不良反应，19例患者（12.5%）出现实验室检查结果异常。根据上述结果，IPM/CS被认为是治疗伴有造血系统疾病的严重感染的有效抗生素。
